Duke University Medical Center
Durham, North Carolina, 27710, United States
NCT Number: NCT07525063
This pilot feasibility study aims to evaluate transcranial magnetic stimulation (TMS) targeting the prefrontal cortex in patients with fibromyalgia syndrome (FMS). The study will assess preliminary efficacy and mechanisms of central nervous system changes using neuroimaging, behavioral tasks, sensory testing, and neuroimmune markers. Participants will undergo MRI scans, multi-day TMS sessions, and complete questionnaires. The goal is to generate pilot data for future trials on neuromodulation for chronic pain.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
Durham, North Carolina, 27710, United States
This is a study to compare activity in the brains of female adults with chronic pain before and after a new intervention. What the researchers learn by doing this study may help them understand how the brain works and how to develop new and targeted treatments for adults with chronic pain.
Female participants in this study will come to Duke Hospital for up to 6 visits. First, there is an MRI scan visit. Then, there are 4 intervention (TMS) visits, one after the other over 4 days. Next, there is an identical follow up MRI scan visit. Afterwards, there is a one month, three month, and six month follow up that can be completed remotely.
During each of 2 MRI study visits, participants will:
During each of 4 TMS study visits, participants will:
Participation is complete once the requested study visits and follow-up questionnaires have been completed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusions:
Exclusions:
TMS-Specific Exclusions:
Due to the contributions of hormones to the conditions under study in this project, female eligibility in this study will be defined as an individual who is female sex at birth and currently female sex
TMS protocol delivered via MagPro X100 stimulator with figure-8 coil targeting prefrontal cortex.
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
PROMIS Short Form - Pain Intensity (3a) is a 3-item measure which includes questions of pain at its worst (past 7 days), average pain (past 7 days), and pain right now (at time of survey). Each item is rated from No Pain (1) to Very Severe (5).
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
The PROMIS Fatigue Computer Adaptive Test (CAT) is a dynamic, patient-reported outcome tool that measures fatigue severity (intensity, frequency, and impact) over the past seven days. Using item response theory (IRT), it selects the next best question based on previous answers, typically requiring only 4-6 items to produce highly precise, reliable scores while minimizing patient burden. Scoring: Results are reported as T-scores, where 50 is the general population mean and 10 is the standard deviation. A T-score of 60 or higher is one standard deviation worse than average.
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
The Montreal Cognitive Assessment (MoCA) is a valid, 30-point screening tool used to assess "fibro fog"-the cognitive dysfunction, memory loss, and attention difficulties associated with fibromyalgia. Scoring: The test is scored out of 30 points. A score of 26-30 is considered normal, while scores below 26 may indicate mild cognitive impairment (19-25) or more advanced impairment (below 21). One point is added for individuals with 12 years or fewer of formal education.
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
Functional Magnetic Resonance Imaging (fMRI) will be used to track blood-oxygen-level-dependent (BOLD) signals during reward anticipation and feedback. BOLD signal change identifies neural activity in the brain which will be reported as normalized to percent signal change (Avg%Δ) relative to the mean image intensity to allow for cross-subject comparison (i.e., arbitrary units scale).
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
Functional connectivity in fMRI measures the statistical dependencies (similarities) between blood oxygen level-dependent (BOLD) signal time series from different brain regions. Typically quantified using Pearson's correlation or covariance in either resting-state or task-based studies, it identifies synchronized activity indicating functionally linked regions/networks.
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
Amplitude of Low-Frequency Fluctuations (ALFF) in fMRI measures the intensity of spontaneous brain activity by calculating the square root of the power spectrum (via Fast Fourier Transform) within a specific low-frequency range. It quantifies the amplitude of resting-state BOLD signal oscillations, typically after voxel-wise standardization (i.e., arbitrary units scale).
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
Cytokines in blood, when measured using Meso Scale Discovery (MSD) multiplex immunoassay kits, are typically reported in picograms per milliliter (pg/mL). MSD assays are known for their high sensitivity, capable of detecting analytes in the low pg/mL to sub-pg/mL range.
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
The PEG scale (Pain, Enjoyment, General Activity) is a 3-item, patient-reported tool that measures chronic pain intensity and its interference with daily life. It uses a 0-10 numerical rating scale (NRS) for each item, where 0 represents "no pain/no interference" and 10 represents "worst pain/complete interference," averaging the three to produce a final score.
Time frame: Baseline MRI and post-intervention MRI (approximately 3 weeks)
The Fibromyalgia Impact Questionnaire (FIQ) and its revision (FIQR) measure the overall impact of fibromyalgia on a patient's life, including physical function, work difficulty, pain, fatigue, sleep quality, and psychological symptoms over the past 7 days. Total scores range from 0 to 100, with higher scores indicating greater severity.
Duke University
Other
Acronym: PRANCIR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07591766
Behavior, Fibromyalgia
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07495943
Anxiety Disorders, Behavior
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07344675
Chronic Pelvic Pain, Chronic Pelvic Pain Syndrome (CPPS)
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06929598
Agnosia, Chronic Pain
Tel Aviv, Israel
View Trial Details